News

Streck Announces Series B Investment in Ceres Nanosciences

La Vista, Nebraska – Streck announced today a Series B investment in Ceres Nanosciences (Ceres). The funds from this investment will be used to accelerate the development and commercialization of both diagnostic and research use products utilizing Ceres’ Nanotrap® technology platform.​

“Streck has a deep presence in and knowledge of the diagnostics industry and shares our commitment to building long-term relationships with partners and customers,” said Ceres CEO Ross Dunlap. “We are thrilled to have Streck’s support and guidance in this next, exciting phase of our growth.”

Announcement_Graphics_FB_1200x630.jpg

This investment builds on the pre-existing partnership between Ceres and Streck, which has produced the Streck® Viral Extraction Kit, powered by Nanotrap technology, and a global distribution agreement covering Nanotrap particles for virus capture and concentration from wastewater samples.

“Ceres has a fantastic reputation for delivering innovative, high-quality products,” said Matthew Kreifels, Vice President of Sales. “We look forward to the positive impacts this partnership will have and working closely with their team to maximize the company’s impacts in the public health and diagnostics arenas.”

Streck will join Series A investor GreyBird Ventures on Ceres’ Board of Directors.

Read more here.

​

“We are very happy with our investment in Ceres and are pleased that Streck has joined us,” said Tom Miller, GreyBird Ventures Co-Founder and Chair of Ceres’ Board. “A world-class company like Streck as a strategic partner, coupled with a Ceres team that has demonstrated the ability to solve some of the most difficult problems in health care diagnostics, is a clear catalyst for accelerated growth.”

Recent News

11/18/2026

GeneDx Announces Leadership Transition

GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr. Cunningham succeeds Katherine Stueland, who has announced that …

11/17/2026

LifeNet Health Announced that Rony Thomas has Resigned

LifeNet Health announced that Rony Thomas has resigned as President and Chief Executive Officer and as a member of its Board of Directors, effective November 13, 2026. Mr. Thomas led LifeNet Health since 2004. During his tenure, the organization grew into a global leader in organ and tissue procurement and regenerative medicine. “On behalf of …

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …